Call(WhatsApp Us)
+8615360806100Email Us
cherry@laeyo.comSee the factory by live video walkthrough
Book an on-site factory visit in GuangzhouA 45 °C storage study is one of the most frequently requested documents in Gulf skincare sourcing — and one of the most frequently misread. It is a stress screen, not a shelf-life certificate. It…
A 45 °C storage study is one of the most frequently requested documents in Gulf skincare sourcing — and one of the most frequently misread. It is a stress screen, not a shelf-life certificate. It can tell you whether an emulsion is likely to split, a fragrance to turn, a color to drift, or a viscosity to collapse under the heat a Gulf warehouse, container, or car boot will deliver. It cannot, on its own, prove a 24- or 36-month shelf life, and it should never be converted into real time with a fixed multiplier. This guide explains what a 45 °C study actually demonstrates, what it leaves open, and the exact evidence a buyer should request before approving a skincare SKU for GCC distribution. Informational only, not legal advice.
Elevated-temperature testing accelerates certain chemical and physical reactions so that weaknesses surface in weeks rather than years. Its value is in early risk detection: separation, color shift, odor change, pH drift, viscosity drift, and packaging interaction. Its boundary is equally important — an accelerated result is a prediction under stress, and it may over-react or miss mechanisms that only appear under real conditions. It is supportive evidence, not the core evidence.
The core evidence is the real-time, long-term study run at the storage condition the product is actually intended to face. Accelerated data helps you interpret and prioritize; it does not replace that trend line.
| Storage condition | What it is meant to reveal | How far a buyer can rely on it |
|---|---|---|
| Long-term / target real-time condition | The true change trend under the intended storage environment | Core evidence. The condition must match where the product will actually be stored and sold |
| Elevated temperature (e.g., 40 °C or 45 °C) | Early separation, color shift, odor change, viscosity drift, pH movement | Supportive and screening only. No fixed multiplier conversion (e.g., “1 month at 45 °C = X months at ambient”) |
| Low temperature (e.g., 5 °C) | Crystallization, haze, turbidity, pumpability, rheology change | Risk-based. Particularly relevant to oily, surfactant, and polymer systems |
| Freeze–thaw cycles | Physical stability after cold shock in the distribution chain | As needed. Not mandatory for every SKU; driven by route and season |
| Thermal cycling | Repeated stress at interfaces and structures as temperature swings | As needed. Strongly relevant to Gulf container and warehouse exposure |
| Light exposure (xenon or defined fluorescent source) | Color, fragrance, and active degradation where the pack transmits light | Required where light reaches the product. Needs a strict dark control |
| Centrifuge | Rapid R&D screening of emulsion separation | Screening only. Cannot substitute for a long-term study |
There is no universal stability table that applies to all products. Conditions must be set from the specific formula, pack, and risk profile. A buyer who receives a generic “we do 45 °C for 3 months for everything” answer has received a service description, not a risk assessment.
Country-average climate is a poor proxy for what a product experiences. The realistic exposure chain usually includes some combination of:
This is why a well-designed protocol usually combines long-term data, elevated temperature, thermal cycling, and — where the pack transmits light — a standardized light study with a dark control. Testing a product by “leaving it near a window” is not a light study; it is an anecdote. The source must be describable and reproducible.
Fragrance oils, natural botanical extracts, pigments, glass coating, inks, and label stock are all light-sensitive materials. Skincare categories at higher risk include:
A credible manufacturer runs a stability risk assessment before writing the protocol. If you are asked nothing about your product, market, or pack before a protocol appears, that is a documentation warning sign. The assessment should take in at least the following inputs:
Ask for this assessment in writing. It is the document that justifies why your protocol looks the way it does — and it is the first thing a serious buyer should be able to forward internally.
Do not accept a summary line such as “stable for 3 years.” Request the protocol and the raw data package. A reviewable protocol typically specifies:
Heat accelerates interaction between formula and pack. Typical Gulf-relevant packaging failures include:
Packaging compatibility is a separate deliverable from formula stability. Request it explicitly, and make sure transport and vibration simulation is included where the distribution route justifies it.
Shelf life is a scientific decision, not a data extrapolation. Cosmetic shelf life is conventionally understood as the period during which the product keeps its normal appearance, function, and safety under expected conditions. That determination should rest on:
Labelling rules differ by market and by product classification. In the US, ordinary cosmetics do not carry a mandatory expiry-date requirement; in other jurisdictions and for products that fall into a drug or OTC category, different rules apply. Classification and label decisions belong with your regulatory reviewer, not with the factory alone, and not with a blog post.
Two questions look minor until a shipment is held at the border.
Bulk hold time. How long may the filled-bulk sit in a tank before filling? A validated hold-time protocol defines the approved duration, storage condition (typically closed system), mixing condition, and temperature. If the bulk is held beyond the approved window, it is not automatically scrap — but it requires a documented release decision, usually including microbial re-test. Ask for the approved hold time and the condition it was validated under.
Post-launch monitoring. A credible plan places retention samples of a commercial batch in a controlled environment and re-tests them at defined timepoints — for example 0, 3, 6, 12, 18, 24, and 36 months — comparing against the initial specification. This is how a shelf-life claim stays true after launch, and how a complaint becomes traceable rather than anecdotal.
| Symptom | Root cause | Prevention | Evidence to request |
|---|---|---|---|
| Serum darkens or turns after two months in market | Oxidation or light-driven degradation; unstable pigment or fragrance | Include elevated temperature and light testing with dark control; adjust pack or antioxidant system | Light stability report with dark control, plus 45 °C appearance and color data by timepoint |
| Emulsion separates in retail stock | Emulsifier system marginal at high temperature; no thermal cycling performed | Screen at elevated temperature, then confirm with real-time data; review emulsifier and viscosity targets | Full stability protocol plus timepoint records showing separation observations |
| Product leaks in transit | Closure or pump not validated under pressure and temperature change | Run transport and thermal cycling with the commercial pack | Packaging compatibility and transport simulation report |
| Pump no longer dispenses the correct dose | Viscosity drift at high temperature changes dose or prime behavior | Test dose performance across the temperature profile in the final pack | Dose and prime data at 0 and at end-of-study timepoints |
| Label lifts or ink smears | Adhesive or ink not validated for humidity and heat | Include label stock and print in the compatibility scope | Label adhesion and humidity exposure report from the packaging supplier |
| Micro counts rise after consumer use | Preservative system under-challenged; high-risk format; no use simulation | Run preservative efficacy testing plus challenge under realistic use | Preservative efficacy report, microbial limits by timepoint, and use-condition rationale |
| Documentation audit fails | Missing COA, SDS, or stability and micro reports; mismatched INCI between spec and label | Build a document pack before purchase orders, not after | Signed document pack: COA, SDS, INCI, spec sheet, stability, micro, batch record |
Real-time stability runs in real time. That is not negotiable, and any partner promising a 36-month claim from a 90-day study is selling you risk. What can be compressed is decision sequencing: locking packaging early, running screening in parallel, and staging the commercial decision.
| Phase | Buyer action | Manufacturer action | Evidence output |
|---|---|---|---|
| Risk assessment | Share market, dosage form, use scenario, distribution route | Produce written risk assessment and draft protocol | Risk assessment document and protocol |
| Packaging lock | Approve pack, closure, label stock | Confirm compatibility scope and order components | Approved packaging spec and compatibility plan |
| Screening | Review early warning signals | Run elevated temperature, cycling, light where relevant | Interim stability report with timepoint data |
| Pilot run | Approve bulk and fill for the pilot batch | Produce pilot batch, initiate long-term study and retention samples | Batch record, COA, study initiation record |
| Label and claim review | Align claims with data available; route to regulatory | Supply substantiation package | Claim substantiation file and label review sign-off |
| Long-term data | Accept staged commercial decisions with documented risk | Continue timepoints; issue updated reports | Long-term stability reports at each milestone |
| Document handoff | Archive the full pack per SKU | Deliver complete documentation set | Full evidence pack including micro and compatibility |
No. It provides early risk information and supports your judgment. The shelf-life claim should rest primarily on real-time data at the intended storage condition. Treat any fixed conversion factor between accelerated and real time as a claim to challenge.
Not necessarily at identical conditions or durations. The protocol should follow the risk assessment. A simple anhydrous balm and a light, fragrance-heavy aqueous serum do not carry the same risk profile, and the testing should reflect that difference.
They are risk-based. Freeze–thaw matters where the distribution route includes cold exposure; thermal cycling is particularly relevant where containers and warehouses swing between daytime peaks and night-time lows. Document the rationale either way.
This is a commercial risk decision, and many brands stage launches while real-time data accumulates. What should not be staged are safety-critical items: preservative efficacy, microbial limits, and packaging compatibility should be resolved before commercial shipment.
A report that summarizes results without the protocol, timepoints, batch identity, acceptance criteria, and raw data. If the summary cannot be traced back to test records, it will not survive an audit or a serious retail technical review.
If you are sourcing skincare for GCC distribution, ask for the protocol and the risk assessment — not the conclusion. A partner who can show you the conditions, the timepoints, and the packaging scope is a partner you can defend internally.